GlaxoSmithKline, Save The Children Form Partnership To Save Children’s Lives
“GlaxoSmithKline [GSK] is giving Save the Children $23 million and entering into a five-year partnership with the charity to try to save the lives of one million children,” the Associated Press/Bloomberg Businessweek reports (Straziuso, 5/9). “The initiative launched by the two organizations on Thursday in Kenya will see Save the Children with a seat on the R&D board, advising on new products for the poorest countries, while GSK also pays for the training of more health care workers who will dispense medicines and give vaccines,” The Guardian writes, adding, “Save the Children’s Chief Executive Justin Forsyth, at the launch in Kenya with GSK’s Chief Executive Sir Andrew Witty, described it as ‘a ground breaking partnership’ which ‘involves both organizations working in genuinely new ways to save the lives of a million children'” (Boseley, 5/9).
GSK “said the partnership would set a new standard for how companies and charities could work together,” according to BBC News (5/10). “GSK said it would give at least £15 million ($23.25 million) over the course of the partnership, partly in donations from its 104,000 staff worldwide, as well as contributions through research and development (R&D) programs,” Thomson Reuters Foundation writes. The companies “have agreed to work together for an initial five-year period, but this could be extended if the initiative proves successful, a GSK spokeswoman told Thomson Reuters Foundation,” the news service states, adding, “Both Witty and Forsyth said they saw the partnership as a long-term collaboration” (Rowling, 5/9).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.